Skip to main content
Erschienen in: European Journal of Epidemiology 1/2011

01.01.2011 | DIABETES

Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes

verfasst von: Jukka Montonen, Dagmar Drogan, Hans-Georg Joost, Heiner Boeing, Andreas Fritsche, Erwin Schleicher, Matthias B. Schulze, Tobias Pischon

Erschienen in: European Journal of Epidemiology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The contribution of different biological pathways to the development of type 2 diabetes was quantified in a case-cohort design based on circulating blood biomarkers from participants aged 35–65 years in the EPIC–Potsdam Study. The analytic sample included 613 participants with incident diabetes and 1965 participants without diabetes. The proportion that each biomarker contributed to the risk of diabetes was quantified using effect decomposition method. Summarized risk of each biomarker was estimated by an index based on quintiles of gamma-glutamyltransferase (GGT), HDL-cholesterol, hs-CRP, and adiponectin. Cox proportional hazard regression was used to estimate relative risks adjusted for age, sex, body mass index, waist-circumference, education, sport activity, cycling, occupational activity, smoking, alcohol intake, and consumptions of red meat, coffee and whole grain bread. Adiponectin explained a total of 32.1% (CI = 16.8, 49.1%) of the risk related to index. For the other biomarkers the corresponding proportions were 23.5% (CI = 10.1, 37.8%) by HDL-cholesterol, 21.5% (CI = 11.5, 32.8%) by GGT, and 15.5% (CI = 4.44, 27.3%) by hs-CRP. The results support the hypothesis that the different biological pathways reflected by GGT, HDL-cholesterol, hs-CRP and adiponectin independent from each other contribute to the risk of type 2 diabetes. Of these pathways the highest contribution was observed for adiponectin which contributed one-third to the risk and that equal proportion was contributed by GGT and HDL-cholesterol, although the contribution of inflammation was lower.
Literatur
1.
Zurück zum Zitat Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia. 2008;51:926–40.CrossRefPubMed Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia. 2008;51:926–40.CrossRefPubMed
2.
Zurück zum Zitat Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.CrossRefPubMed Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.CrossRefPubMed
3.
Zurück zum Zitat Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2009;302:179–88.CrossRefPubMed Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2009;302:179–88.CrossRefPubMed
4.
Zurück zum Zitat Schulze MB, Weikert C, Pischon T, Bergmann MM, Al-Hasani H, Schleicher E, et al. Use of Multiple Metabolic and Genetic Markers to Improve the Prediction of Type 2 Diabetes: the EPIC-Potsdam Study. Diabetes Care. 2009;32:2116–9.CrossRefPubMed Schulze MB, Weikert C, Pischon T, Bergmann MM, Al-Hasani H, Schleicher E, et al. Use of Multiple Metabolic and Genetic Markers to Improve the Prediction of Type 2 Diabetes: the EPIC-Potsdam Study. Diabetes Care. 2009;32:2116–9.CrossRefPubMed
5.
Zurück zum Zitat Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013–8.CrossRefPubMed Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013–8.CrossRefPubMed
6.
Zurück zum Zitat Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–74.CrossRefPubMed Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–74.CrossRefPubMed
7.
Zurück zum Zitat Chen C, Wang H, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med. 2003;22:3449–59.CrossRefPubMed Chen C, Wang H, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med. 2003;22:3449–59.CrossRefPubMed
8.
Zurück zum Zitat Drogan D, Weikert C, Dierkes J, Klipstein-Grobusch K, Buijsse B, Möhlig M, et al. Plasma gamma-glutamyltransferase, cysteinyl-glycine, and oxidized low-density lipoprotein: a pathway associated with myocardial infarction risk? Arterioscler Thromb Vasc Biol. 2010;30:2053–8.CrossRefPubMed Drogan D, Weikert C, Dierkes J, Klipstein-Grobusch K, Buijsse B, Möhlig M, et al. Plasma gamma-glutamyltransferase, cysteinyl-glycine, and oxidized low-density lipoprotein: a pathway associated with myocardial infarction risk? Arterioscler Thromb Vasc Biol. 2010;30:2053–8.CrossRefPubMed
9.
Zurück zum Zitat Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24.CrossRefPubMed Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24.CrossRefPubMed
10.
Zurück zum Zitat Boeing H, Wahrendorf J, Becker N. EPIC-Germany–A source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43:195–204. Boeing H, Wahrendorf J, Becker N. EPIC-Germany–A source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43:195–204.
11.
Zurück zum Zitat Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43:205–15. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43:205–15.
12.
Zurück zum Zitat Bohlscheid-Thomas S, Hoting I, Boeing H, Wahrendorf J. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(Suppl 1):S59–70.CrossRefPubMed Bohlscheid-Thomas S, Hoting I, Boeing H, Wahrendorf J. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(Suppl 1):S59–70.CrossRefPubMed
13.
Zurück zum Zitat Klipstein-Grobusch K, Georg T, Boeing H. Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol. 1997;26(Suppl 1):S174–80.CrossRefPubMed Klipstein-Grobusch K, Georg T, Boeing H. Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol. 1997;26(Suppl 1):S174–80.CrossRefPubMed
14.
Zurück zum Zitat Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52:1165–72.CrossRefPubMed Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52:1165–72.CrossRefPubMed
15.
Zurück zum Zitat Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–8.CrossRefPubMed Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–8.CrossRefPubMed
16.
Zurück zum Zitat Fieller E. The biological standardization of insulin. J Roy Stat Soc. 1940;7(Supplement):1–15. Fieller E. The biological standardization of insulin. J Roy Stat Soc. 1940;7(Supplement):1–15.
17.
Zurück zum Zitat Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741–51.CrossRefPubMed Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741–51.CrossRefPubMed
18.
Zurück zum Zitat Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.CrossRefPubMed Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.CrossRefPubMed
19.
Zurück zum Zitat Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–53.CrossRefPubMed Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–53.CrossRefPubMed
20.
Zurück zum Zitat Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–9.CrossRefPubMed Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–9.CrossRefPubMed
21.
Zurück zum Zitat Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007;7:24–9.CrossRefPubMed Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007;7:24–9.CrossRefPubMed
22.
Zurück zum Zitat Khan HA. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007;44:193–200.CrossRef Khan HA. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007;44:193–200.CrossRef
23.
Zurück zum Zitat Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, et al. Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care. 2009;32:1550–2.CrossRefPubMed Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, et al. Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care. 2009;32:1550–2.CrossRefPubMed
24.
Zurück zum Zitat Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286:327–34.CrossRefPubMed Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286:327–34.CrossRefPubMed
25.
Zurück zum Zitat Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56:872–8.CrossRefPubMed Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56:872–8.CrossRefPubMed
26.
Zurück zum Zitat Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005;28:2497–500.CrossRefPubMed Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005;28:2497–500.CrossRefPubMed
27.
Zurück zum Zitat Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47:1403–10.CrossRefPubMed Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47:1403–10.CrossRefPubMed
28.
Zurück zum Zitat Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700.CrossRefPubMed Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700.CrossRefPubMed
29.
Zurück zum Zitat Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7.CrossRefPubMed Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7.CrossRefPubMed
30.
Zurück zum Zitat Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812–7.CrossRefPubMed Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812–7.CrossRefPubMed
31.
Zurück zum Zitat Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–600.CrossRefPubMed Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–600.CrossRefPubMed
32.
Zurück zum Zitat Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384–9.CrossRefPubMed Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384–9.CrossRefPubMed
33.
Zurück zum Zitat Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study. J Clin Endocrinol Metab. 2009;94:2099–105.CrossRefPubMed Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study. J Clin Endocrinol Metab. 2009;94:2099–105.CrossRefPubMed
34.
Zurück zum Zitat Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52:1040–7.CrossRefPubMed Lee C, Adler A, Sandhu M, Sharp S, Forouhi N, Erqou S, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52:1040–7.CrossRefPubMed
35.
Zurück zum Zitat Little RR, England JD, Wiedmeyer HM, Madsen RW, Pettitt DJ, Knowler WC, et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia. 1994;37:252–6.CrossRefPubMed Little RR, England JD, Wiedmeyer HM, Madsen RW, Pettitt DJ, Knowler WC, et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia. 1994;37:252–6.CrossRefPubMed
36.
Zurück zum Zitat Yoshinaga H, Kosaka K. High glycosylated hemoglobin levels increase the risk of progression to diabetes mellitus in subjects with glucose intolerance. Diabetes Res Clin Pract. 1996;31:71–9.CrossRefPubMed Yoshinaga H, Kosaka K. High glycosylated hemoglobin levels increase the risk of progression to diabetes mellitus in subjects with glucose intolerance. Diabetes Res Clin Pract. 1996;31:71–9.CrossRefPubMed
37.
Zurück zum Zitat Narayan KM, Hanson RL, Pettitt DJ, Bennett PH, Knowler WC. A two-step strategy for identification of high-risk subjects for a clinical trial of prevention of NIDDM. Diabetes Care. 1996;19:972–8.CrossRefPubMed Narayan KM, Hanson RL, Pettitt DJ, Bennett PH, Knowler WC. A two-step strategy for identification of high-risk subjects for a clinical trial of prevention of NIDDM. Diabetes Care. 1996;19:972–8.CrossRefPubMed
38.
Zurück zum Zitat Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care. 2000;23:1770–3.CrossRefPubMed Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care. 2000;23:1770–3.CrossRefPubMed
39.
Zurück zum Zitat Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007;120:720–7.CrossRefPubMed Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007;120:720–7.CrossRefPubMed
40.
Zurück zum Zitat Michaelis D, Jutzi E. Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR: Alters- und geschlechtsspezifische Inzidenz- und Prävalenztrends im Zeitraum 1960–1987 (Article in German). Z Klin Med. 1991;46:59–64. Michaelis D, Jutzi E. Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR: Alters- und geschlechtsspezifische Inzidenz- und Prävalenztrends im Zeitraum 1960–1987 (Article in German). Z Klin Med. 1991;46:59–64.
41.
Zurück zum Zitat Fleiss JL. The design and analysis of clinical experiments. New York: Wiley and Sons; 1986. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley and Sons; 1986.
42.
Zurück zum Zitat Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, et al. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers. 2006;11:370–82.CrossRefPubMed Al-Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, et al. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers. 2006;11:370–82.CrossRefPubMed
43.
Zurück zum Zitat Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155–60.CrossRefPubMed Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155–60.CrossRefPubMed
44.
Zurück zum Zitat Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003;49:650–2.CrossRefPubMed Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003;49:650–2.CrossRefPubMed
45.
Zurück zum Zitat Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002;31:163–5.CrossRefPubMed Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002;31:163–5.CrossRefPubMed
46.
Zurück zum Zitat Petersen ML, Sinisi SE, van der Laan MJ. Estimation of direct causal effects. Epidemiology. 2006;17:276–84.CrossRefPubMed Petersen ML, Sinisi SE, van der Laan MJ. Estimation of direct causal effects. Epidemiology. 2006;17:276–84.CrossRefPubMed
47.
Zurück zum Zitat Kaufman JS, Maclehose RF, Kaufman S. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov. 2004;1:4.CrossRefPubMed Kaufman JS, Maclehose RF, Kaufman S. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov. 2004;1:4.CrossRefPubMed
48.
Zurück zum Zitat Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefPubMed Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefPubMed
49.
Zurück zum Zitat Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring). 2008;16:241–56.CrossRef Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring). 2008;16:241–56.CrossRef
Metadaten
Titel
Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes
verfasst von
Jukka Montonen
Dagmar Drogan
Hans-Georg Joost
Heiner Boeing
Andreas Fritsche
Erwin Schleicher
Matthias B. Schulze
Tobias Pischon
Publikationsdatum
01.01.2011
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 1/2011
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-010-9539-0

Weitere Artikel der Ausgabe 1/2011

European Journal of Epidemiology 1/2011 Zur Ausgabe